NCT03448978 - Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 8, 2018

Primary Completion Date

April 19, 2021

Study Completion Date

June 3, 2021

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL

Descartes-08

autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor

DRUG

Fludarabine

intravenous fludarabine

DRUG

Cyclophosphamide

intravenous cyclophosphamide

Trial Locations (3)

The Center for Cancer and Blood Disorders, Bethesda

Virgina Cancer Specialists, Fairfax

University of Oklahoma Health Sciences Center, Oklahoma City